Efficacy and safety results from CARE-MS I: A phase 3 study comparing alemtuzumab and interferon-β-1a

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2011
This article has no abstract
Epistemonikos ID: 03addc7959d49641e17f3e49bd3482b944b2d4eb
First added on: Apr 30, 2026